Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)
Ali Ekin, Salim Misirci, Nihal Lermi, Nagehan Dik Kutlu, Belkis Nihan Coskun, Burcu Yagız, Ediz Dalkılıç, Yavuz Pehlivan · Aktuelle Rheumatologie · 2025 · Heft 01 · S. 71-82
Bibliografische Angaben
Zusammenfassung
Abstract Backgorund Rituximab is an anti-CD20 monoclonal antibody used in the treatment of rheumatoid arthritis. The molecule CT -P10 is a biosimilar of rituximab used in rheumatoid arthritis and has the same safety and efficacy. Material and methods The aim of our study was to investigate whether drug efficacy decreases after the mandatory switch from originator rituximab to biosimilar rituximab, whether there is an increase in disease activity indices in patients with rheumatoid arthritis receiving rituximab, that could indicate decreased efficacy, and whether the frequency of adverse events related to drug sa…
